PO.CTP01.02 · 进行中的临床试验
Phase I and Phase II Clinical Trials in Progress
- CT267 CT267 Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes/neoplasms Dennise A. de Jesús-Díaz, Aaron Goldberg, Steve Abella, Caroline M. Robb, Michael Schelle, Gregory Crimmins
- CT268 CT268 Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL) Martin Hutchings, Andrew Zelenetz, Jacob H. Christensen, Almudena Cascales Hernandez, Sarit Assouline, Luis E. Malpica Castillo, Shalin Kothari, Dipenkumar Modi, Miguel A. Canales Albendea, Damian Cubillas, Alejandro M. Garcia-Sancho, Catherine M. Diefenbach, John Kuruvilla, Paolo F. Caimi, Krish Patel, Sean Landrette, Eric Zhi, Yuanyuan Zhang, Roland Meier, Mathew J. Matasar
- CT269 CT269 Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies Joseph P. McGuirk, Rupal Soder, Ramesh Balusu, Nathaniel Dudley, Louisa Wirthlin, Tyce Bruns, David Akhavan, Scott J. Weir, Sunil Abhyankar
- CT270 CT270 Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas Giselle Saulnier Sholler, Genevieve Bergendahl, Kevin Bielamowicz, Derek Hanson, Deanna Mitchell, David Hoogstra, Arthur Berg, William Ferguson, Abigail Moore, Jacqueline Kraveka
- CT271 CT271 Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors Chandrika Behura, Genevieve Bergendahl, Julie Steinbrecher, Shouhao Zhou, William Ferguson, Jacqueline Kraveka, Kevin Mulieri, Sinisa Dovat, Abigail Moore, Giselle Saulnier Sholler
-
-
- CT274 CT274 Inhibiting 26S proteosome with sequential bortezomib and temozolomide garners 5 months prolonged survival in recurrent MGMT -negative GBM through amplified tyrosine kinase receptor signaling to avail NF-kB mechanistic target in NCT03643549 Phase IB/II trial Dorota Goplen, Mohummad Aminur Rahman, Surendra Kumar, Marianne H. Hannisdal, Victoria Arnesen, Andreas Waha, Leif Oltedal, Judit Haasz, Jorunn Brekke, Tora S. Solheim, Petter Brandal, Stein A. Lie, Martha Chekenya
- CT275 CT275 ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586) Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci
-
- CT277 CT277 IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC) Jason Mouabbi, Paula Pohlmann, Rachel Layman, Roland Bassett, Lavinia Middleton, Bora Lim, Toni Zaayman, Krystle Nomie, Evgeny Barykin, Anastasiya Evdokimova, Mariana Chavez-MacGregor, Jennifer Litton, Sharon Giordano, Funda Meric-Bernstam
-
- CT280 CT280 A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions: Impact of treatment selection, oncologic outcomes, and treatment-related adverse events (PROMPT-Bx) Brent Mabey, Lauren Lenz, Thaylon Davis, Alexander Gutin, Katherine Johansen Taber, Dale Muzzey, Jeff Jasper, Matthew Schiewer
-
-
- CT283 CT283 Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients with peritoneal-only metastasis from pancreatic ductal adenocarcinoma Julien T. Hohenleitner, Oliver J. Standring, Amber N. Habowski, Murtuza Hassan, Hai Huang, Matthew J. Weiss, Craig E. Devoe, Sepideh Gholami, Arvind Rishi, Daniel A. King, David A. Tuveson, Richard Whelan, Danielle K. Deperalta
- CT284 CT284 First-in-human, phase I/II study of BPI-572270, an oral RAS(ON) multi tri-complex inhibitor, in patients with RAS-mutated advanced solid tumors Zhengbo Song, Han Han, Xiang Yang, Wenmao Wu, Jing Guo, Hong Lan, Quan Zhou, Hui Chen, Weijie Li, Pengxiang Wu, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding
-
-
- CT287 CT287 A first-in-human (FIH), Phase 1/2, dose-escalation and dose-optimization study of central nervous system (CNS)-penetrant, PARP1-selective inhibitor EIK1004 in patients with advanced solid tumors with or without brain metastases Timothy A. Yap, Jian Zhang, Yanhua Xu, Sanum Chaudry, Kevin H. Eng, Yawei Zhang, Viola J. Chen, Gerald Falchook
-
-
- CT290 CT290 NTS071-101: A phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in patients with advanced solid tumors harboring a TP53 Y220C mutation Qiancheng Shen, Yan Xu, Yinqun Wu, Shuhan Shen, Guoqiang Zhou
- CT291 CT291 First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activation, promising antitumor activity, and a manageable safety profile in advanced or metastatic melanoma Jun Guo, Lu Si, Lili Mao, Weidong Jiang, Haixiang Wu, Kahaerjiang Abuduwaili, Yi Zhao, Lianlian Jiang, Yutao Gao, Jiangfeng Fan, Naijun Tang
-
-
-
- CT295 CT295 Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors Ciara M. Kelly, Reinhard von Roemeling, Monali Banerjee, Viswatej Avutu, Olayade Babatunde, Lauren Banks, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Grace Gray, Camron Clark, Mary Louise Keohan, Robert G. Maki, Sujana Movva, Damon Reed, Kelly Schroeder, Li-Xuan Qin, Phillip Wong, Sandip Middya, Ritesh Shrivastava, Debjani Chakraborty, Rajib Ghosh, Sourav Basu, Arjun Surya, William D. Tap, Sandra P. D'Angelo
